Key facts
- This page summarizes Dr. Tushar Shah's Form 4 filing for Liquidia Corp (LQDA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 19 Jan 2022, 15:36.
Dr. Tushar Shah - 16 Jan 2022 Form 4 Insider Report for Liquidia Corp (LQDA)
- Reporting relationship
- CMO and Head of R&D
- Issuer ticker
- LQDA
- Reported as of
- 16 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Jan 2022, 15:36:06 UTC
- Prior SEC filing
- 12 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Russell Schundler, as attorney-in-fact for Dr. Tushar Shah
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Dr. Tushar Shah filed Form 4 for Liquidia Corp (LQDA) on 19 Jan 2022.
Change
- Previous filing in this sequence was filed on 12 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LQDA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- Price
- $0.000000
- Shares after
- 35,000
- Date
- 16 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,000
- Exercise price
- Footnotes
- F1, F2
LQDA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +70,000
- Change %
- Price
- $0.000000
- Shares after
- 70,000
- Date
- 16 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 70,000
- Exercise price
- $6.25
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter.
Footnote F3
The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 28, 2022 and on the last day of each month thereafter.